Merck and Themis Bioscience of Austria have partnered for an exclusive license agreement and a research collaboration to discover and develop unspecified vaccine candidates. Themis has completed a midstage trial for its vaccine candidate MV-CHIK, which targets chikungunya.
Merck, Austrian biotech to develop undisclosed vaccine candidates
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.